Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer
The study hypothesis is that metronomic treatment is more efficient than standard treatment.
Breast Cancer
DRUG: Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|DRUG: Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)
Primary endpoint is overall response rate i both arms., Response evaluation at 3rd and 6th cycle by resist criterias. The number of patients that respond to treatment in percent of the total number of patients treated., up to 60 month
Time to progression., Number of days from start of treatment to progression of disease assessed up to 60 months, up to 60 month|Overall survival., Number of days from start of treatment to death assessed up to 60 months., up to 60 month
Toxicity, Monitoring side effects of treatment assessed up to 60 months., Side effects of treatment
Purpose: In an open-label randomized phase II trial, patients with metastatic Human Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant WHO performance status \< 3 are randomized to receive either capecitabine (day 1-14) plus vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic (3 days a week).